Virus carrier mediated transduction of the revised platelet factor of 4 cDNA inhibiting angiogenesis

Chronic systemic delivery of therapeutic proteins, such as angiogenesis inhibitors, present some difficultiespharmacological challenge. In order to overcome the problems of such a protein, we constructed a retroviral and adenoviral vectors new modes of expression, secretion of anti-angiogenic protein, platelet factor 4 ( number ). Signaltransduction mediated selective inhibition of endothelial cell proliferation, and lead to less blood to slow tumor growth, in vivo. In addition, tumor associated angiogenesis inhibition and animal survival is prolonged, transduction after established glioma spf4-expressing adenovirus vector. These data support the concept, targeted antiangiogenic, using Villari mediated gene transfer, is a promising strategy for antiangiogenic therapy.